Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006; 107:77-85.AlettiGDDowdySCGostoutBSJonesMBStanhopeCRWilsonTOAggressive surgical effort and improved survival in advanced-stage ovarian cancerObstet Gynecol2006107778510.1097/01.AOG.0000192407.04428.bb16394043Search in Google Scholar
Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with “biological aggressiveness” and survival? Gynecol Oncol 2001; 82: 435-41.EisenkopSMSpirtosNMProcedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with “biological aggressiveness” and survival?Gynecol Oncol2001824354110.1006/gyno.2001.631311520137Search in Google Scholar
Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-200.OzolsRFBundyBNGreerBEFowlerJMClarke-PearsonDBurgerRAPhase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group studyJ Clin Oncol200321319420010.1200/JCO.2003.02.15312860964Search in Google Scholar
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943-53.VergoteITropéCGAmantFKristensenGBEhlenTJohnsonNNeoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancerN Engl J Med20103639435310.1056/NEJMoa090880620818904Search in Google Scholar
Vergote I, Leunen K, Amant F. Primary surgery or neoadjuvant chemotherapy in ovarian cancer: what is the value of comparing apples with oranges? Gynecol Oncol 2012; 124: 1-2.VergoteILeunenKAmantFPrimary surgery or neoadjuvant chemotherapy in ovarian cancer: what is the value of comparing apples with oranges?Gynecol Oncol20121241210.1016/j.ygyno.2011.11.01022153125Search in Google Scholar
Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2006; 103: 1070-6.BristowREChiDSPlatinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysisGynecol Oncol20061031070610.1016/j.ygyno.2006.06.02516875720Search in Google Scholar
Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 2012; 124: 10-4.ChiDSMusaFDaoFZivanovicOSonodaYLeitaoMMAn analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)Gynecol Oncol201212410410.1016/j.ygyno.2011.08.01421917306Search in Google Scholar
Rosen B, Laframboise S, Ferguson S, Dodge J, Bernardini M, Murphy J, et al. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. Gynecol Oncol 2014; 134: 462-7.RosenBLaframboiseSFergusonSDodgeJBernardiniMMurphyJThe impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancerGynecol Oncol2014134462710.1016/j.ygyno.2014.07.00425026637Search in Google Scholar
Gourley C, McCavigan A, Perren T, Paul J, OgilvieMichie C, Churchman M, et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. [Abstract]. J Clin Oncol 2014; 32(5 Suppl): abstract No. 5502.GourleyCMcCaviganAPerrenTPaulJOgilvieMichieCChurchmanMMolecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. [Abstract]J Clin Oncol201432(5 Suppl)abstract No. 550210.1200/jco.2014.32.15_suppl.5502Search in Google Scholar
Vergote I, du Bois A, Amant F, Heitz F, Leunen K, Harter P. Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree? Gynecol Oncol 2013; 128: 6-11.VergoteIdu BoisAAmantFHeitzFLeunenKHarterPNeoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?Gynecol Oncol201312861110.1016/j.ygyno.2012.09.01323006973Search in Google Scholar
Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011; 21: 750-5.StuartGCKitchenerHBaconMduBoisAFriedlanderMLedermannJ2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus ConferenceInt J Gynecol Cancer201121750510.1097/IGC.0b013e31821b256821543936Search in Google Scholar
Salani R, Bristow RE. Surgical management of epithelial ovarian cancer. Clin Obstet Gynecol 2012; 55: 75-95.SalaniRBristowRESurgical management of epithelial ovarian cancerClin Obstet Gynecol201255759510.1097/GRF.0b013e31824b462922343231Search in Google Scholar
Thrall MM, Gray HJ, Symons RG, Weiss NS, Flum DR, Goff BA. Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer. Gynecol Oncol 2011; 123: 461-6.ThrallMMGrayHJSymonsRGWeissNSFlumDRGoffBANeoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancerGynecol Oncol2011123461610.1016/j.ygyno.2011.08.030321709521945309Search in Google Scholar
